SEARCH

SEARCH BY CITATION

References

  • 1
    Colom F, Vieta E, Duban C, Pacchiarotti I, Sanchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006;93:1317.
  • 2
    Mazzarini L, Pacchiarotti I, Colom F et al. Predominant polarity and temperament in bipolar and unipolar affective disorders. J Affect Disord 2009;119:2833.
  • 3
    Rosa AR, Andreazza C, Kunz M et al. Predominant polarity in bipolar disorder: diagnostic implications. J Affect Disord 2008;107:4551.
  • 4
    Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ. Predominant polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009;119:2227.
  • 5
    Gonzaléz-Pinto A, Alberich S, Barbieto S et al. Different profile of substance abuse in relation to predominant polarity in bipolar disorder: Vitoria long-term follow-up study. J Affect Disord 2010;124:250255.
  • 6
    First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV–clinical version (SCID-CV; user’s guide and interview). Washington, DC: American Psychiatric Press, Inc, 1997.
  • 7
    Baldessarini RJ, Finklestein SP, Arana GW. Predictive power of diagnostic tests and the effect of prevalence of illness. Arch Gen Psychiatry 1983;40:569573.
  • 8
    Azorin JM, Aubrun E, Bertsch J, Reed C, Gerard S, Lukasiewicz M. Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months–European mania in bipolar longitudinal evaluation of medication. BMC Psychiatry 2009;9:3340.
  • 9
    Pompili M, Rihmer Z, Innamorati M, Lester d, Girardi P, Tatarelli P. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother 2009;9:109136.
  • 10
    Baldessarini RJ, Salvatore P, Khalsa H-MK. Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder. J Affect Disord 2010;126:299302.
  • 11
    Algorta P, Youngstrom EA, Frazier TW, Freeman AJ, Youngstrom JK, Findling RL. Suicidality in peditric bipolar disorder: predictor of outcome of family process and mixed mood presentation? Bipolar Disord 2011;13:7686.
  • 12
    Undurraga J, Baldessarini RJ, Valentí M, Pacchiarotti I, Vieta E. Dissimilar suicidal risk factors in bipolar I and II disorders. J Clin Psychiatry 2011; in press.
  • 13
    Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993;50:448455.
  • 14
    Perugi G, Micheli C, Akiskal HS et al. Polarity of the first episode, clinical characteristics and course of manic depressive illness: systematic retrospective investigation of 320 bipolar-I patients. Compr Psychiatry 2000;47:1318.
  • 15
    Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard first episode mania study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:20992107.
  • 16
    Calabrese JR, Vieta E, El-Mallahk R et al. Mood state at study entry as a predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004;56:957963.
  • 17
    Daban C, Colom F, Sanchez-Moreno J, Garcia-Amador M, Vieta E. Clinical correlates of first-episode polarity in bipolar disorder. Compr Psychiatry 2006;47:433437.
  • 18
    Baldessarini RJ, Salvatore P, Khalsa H-MK et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord 2010;12:264270.
  • 19
    Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden C. Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010;18:143157.
  • 20
    Popovic C, Reinares M, Amann B, Salamero M, Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 2011;213:657667.
  • 21
    Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzaléz-PInto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2011; DOI:10.1016/j.euroneuro.2011.09.008 [Epub ahead of print].
  • 22
    Carlezon WA Jr, Béguin C, Knoll AT, Cohen BM. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther 2009;123:334343.
  • 23
    Rapoport SL, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 2009;61:185209.
  • 24
    Zarate CA Jr, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009;23:569582.
  • 25
    Tondo L, Lepri B, Baldessarini RJ. Risks of suicidal ideation, attempts and suicides among 2826 men and women with types I and II bipolar, and recurrent major depressive disorders. Acta Psychiatr Scand 2007;116:419428.
  • 26
    Baethge C, Baldessarini RJ, Bratti IM, Tondo L. Prophylaxis-latency and outcome in bipolar disorders. Can J Psychiatry 2003;48:449457.
  • 27
    Morselli PL, Elgie R. Global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord 2003;5:265278.
  • 28
    Salvatore P, Baldessarini RJ, Tohen M et al. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry 2009;70:458466.
  • 29
    Benazzi F, Akiskal HS. How best to identify a bipolar-related subtype among major depressive patients without spontaneous hypomania: superiority of age at onset criterion over recurrence and polarity? J Affect Disord 2008;107:7788.
  • 30
    Strakowski SM, Fleck DE, Maj M. Broadening the diagnosis of bipolar disorder: benefits vs. risks. World Psychiatry 2011;10:181186.